Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 109618, 5 pages
http://dx.doi.org/10.4061/2010/109618
Review Article

Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease

1Department for Psychiatry and Psychiatry, University of Erlangen-Nuermberg, Schwabachanlage 6, 91054 Erlangen, Germany
2Clinic of Nuclear Medicine, University of Erlangen-Nuermberg, Schwabachanlage 6, 91054 Erlangen, Germany

Received 8 October 2010; Accepted 15 November 2010

Academic Editor: Adam S. Fleisher

Copyright © 2010 Markus Weih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Knopman, S. T. DeKosky, J. L. Cummings et al., “Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology,” Neurology, vol. 56, no. 9, pp. 1143–1153, 2001. View at Google Scholar · View at Scopus
  2. J. Launes, R. Sulkava, T. Erkinjuntti, P. Nikkinen, L. Lindroth, and K. M. Liewendahl Iivanainen, “99Tcm-HMPAO SPECT in suspected dementia,” Nuclear Medicine Communications, vol. 12, no. 9, pp. 757–765, 1991. View at Google Scholar · View at Scopus
  3. N. J. Dougall, S. Bruggink, and K. P. Ebmeier, “Systematic review of the diagnostic accuracy of 99mTc-HMPAO- SPECT in dementia,” American Journal of Geriatric Psychiatry, vol. 12, no. 6, pp. 554–570, 2004. View at Publisher · View at Google Scholar
  4. M. Weih, M. Krinninger, R. Zimmermann et al., “Vergleichende sensitivität der neurochemischen demenzdiagnostik im liquor und rCBF im 99mTc-SPECT bei patienten mit Alzheimerdemenz,” Fortschritte der Neurologie-Psychiatrie, vol. 77, no. 7, pp. 407–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Schmidt, R. Zimmermann, P. Lewczuk et al., “Confirmation rate of blinded 99mTc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease,” Journal of Neural Transmission, vol. 117, no. 9, pp. 1111–1114, 2010. View at Publisher · View at Google Scholar
  6. F. J. Bonte, M. F. Weiner, E. H. Bigio, and C. L. White, “Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients,” Radiology, vol. 202, no. 3, pp. 793–797, 1997. View at Google Scholar · View at Scopus
  7. W. Jagust, R. Thisted, M. D. Devous et al., “SPECT perfusion imaging in the diagnosis of alzheimer's disease: a clinical-pathologic study,” Neurology, vol. 56, no. 7, pp. 950–956, 2001. View at Google Scholar · View at Scopus
  8. D. P. Devanand, R. L. van Heertum, L. S. Kegeles et al., “99mTc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease,” American Journal of Geriatric Psychiatry, vol. 18, no. 11, pp. 959–972, 2010. View at Publisher · View at Google Scholar
  9. T. Farkas, S. H. Ferris, and A. P. Wolf, “F-2-Deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia,” American Journal of Psychiatry, vol. 139, no. 3, pp. 352–353, 1982. View at Google Scholar · View at Scopus
  10. M. B. Patwardhan, D. C. McCrory, D. B. Matchar, G. P. Samsa, and O. T. Rutschmann, “Alzheimer disease: operating characteristics of PET—a meta-analysis,” Radiology, vol. 231, no. 1, pp. 73–80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Motter, C. Vigo-Pelfrey, D. Kholodenko et al., “Reduction of β-amyloid peptide in the cerebrospinal fluid of patients with Alzheimer's disease,” Annals of Neurology, vol. 38, no. 4, pp. 643–648, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Lewczuk, H. Esselmann, M. Bibl et al., “Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature,” Journal of Molecular Neuroscience, vol. 23, no. 1-2, pp. 115–122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Wiltfang, P. Lewczuk, P. Riederer et al., “Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia,” World Journal of Biological Psychiatry, vol. 6, no. 2, pp. 69–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Mitchell, “CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 9, pp. 966–975, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Lewczuk, H. Esselmann, M. Otto et al., “Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau,” Neurobiology of Aging, vol. 25, no. 3, pp. 273–281, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Lewczuk, R. Zimmermann, J. Wiltfang, and J. Kornhuber, “Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers,” Journal of Neural Transmission, vol. 116, no. 9, pp. 1163–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Lewczuk, H. Kamrowski-Kruck, O. Peters et al., “Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study,” Molecular Psychiatry, vol. 15, no. 2, pp. 138–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B,” Annals of Neurology, vol. 55, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. M. Roe, M. A. Mintun, N. Ghoshal et al., “Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept,” Neurology, vol. 75, no. 1, pp. 42–48, 2010. View at Publisher · View at Google Scholar
  24. G. W. Small, V. Kepe, L. M. Ercoli et al., “PET of brain amyloid and tau in mild cognitive impairment,” New England Journal of Medicine, vol. 355, no. 25, pp. 2652–2663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Vandenberghe, K. van Laere, A. Ivanoiu et al., “18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment a phase 2 trial,” Annals of Neurology, vol. 68, no. 3, pp. 319–329, 2010. View at Publisher · View at Google Scholar
  26. E. R. L. C. Vardy, T. Langheinrich, R. Hinz et al., “POD14 Amyloid PET using 18F-AV-45 in Alzheimer's disease and frontotemporal dementia: first UK results,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 81, no. 11, article e45, 2010. View at Google Scholar
  27. R. McNeill, G. M. Sare, M. Manoharan et al., “Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 4, pp. 350–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. F. Mendez, J. S. Shapira, A. McMurtray, E. Licht, and B. L. Miller, “Accuracy of the clinical evaluation for frontotemporal dementia,” Archives of Neurology, vol. 64, no. 6, pp. 830–835, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Shimizu, H. Hanyu, H. Kanetaka, T. Iwamoto, K. Koizumi, and K. Abe, “Differentiation of dementia with lewy bodies from alzheimer's disease using brain SPECT,” Dementia and Geriatric Cognitive Disorders, vol. 20, no. 1, pp. 25–30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Goto, K. Ishii, T. Uemura et al., “Differential diagnosis of dementia with lewy bodies and alzheimer disease using combined MR imaging and brain perfusion single-photon emission tomography,” American Journal of Neuroradiology, vol. 31, no. 4, pp. 720–725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Tissingh, J. Booij, P. Bergmans et al., “Iodine-123-N-ω-fluoropropyl-2/β-carbomethoxy3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease,” Journal of Nuclear Medicine, vol. 39, no. 7, pp. 1143–1148, 1998. View at Google Scholar · View at Scopus
  32. R. Motter, C. Vigo-Pelfrey, D. Kholodenko et al., “Reduction of β-amyloid peptide in the cerebrospinal fluid of patients with Alzheimer's disease,” Annals of Neurology, vol. 38, no. 4, pp. 643–648, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Zeintl, A. H. Vija, A. Yahil, J. Hornegger, and T. Kuwert, “Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction,” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 921–928, 2010. View at Google Scholar · View at Scopus
  34. M. Pagani, D. Salmaso, G. Rodriguez, D. Nardo, and F. Nobili, “Principal component analysis in mild and moderate Alzheimer's disease—a novel approach to clinical diagnosis,” Psychiatry Research, vol. 173, no. 1, pp. 8–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Merhof, P. J. Markiewicz, G. Platsch et al., “Optimized data preprocessing for multivariate analysis applied to Tc-ECD SPECT data sets of Alzheimer's patients and asymptomatic controls,” Journal of Cerebral Blood Flow and Metabolism. In press. View at Publisher · View at Google Scholar · View at Scopus
  36. W. T. Hu, Z. Wang, V. M.-Y. Lee, J. Q. Trojanowski, J. A. Detre, and M. Grossman, “Distinct cerebral perfusion patterns in FTLD and AD,” Neurology, vol. 75, no. 10, pp. 881–888, 2010. View at Publisher · View at Google Scholar
  37. C. Luckhaus, M. Cohnen, M. O. Flüss et al., “The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia,” Psychiatry Research, vol. 183, no. 1, pp. 44–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Tsolaki, V. Sakka, G. Gerasimou et al., “Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects,” American Journal of Alzheimer's Disease, vol. 16, no. 1, pp. 21–31, 2001. View at Google Scholar
  39. S. J. Colloby, E. K. Perry, S. Pakrasi et al., “Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in alzheimer's disease and dementia with lewy Bodies,” American Journal of Geriatric Psychiatry, vol. 18, no. 1, pp. 86–90, 2010. View at Publisher · View at Google Scholar · View at Scopus